KLK3 and prostate cancer: Black individuals have experienced a consistent and dramatic disparity in prostate cancer death in the US over the past 50 years, despite advances in the diagnosis and treatment of prostate cancer.2,3,4 Level 1 evidence demonstrates a benefit to PSA screening,8,10 but previous studies have shown that rates of PSA screening have declined among Black individuals following the 2012 USPSTF PSA screening recommendation.13